Activation of coagulation factor VII by tissue-type plasminogen activator

American Journal of Hematology

Volumn 61, Issue 1, 1999, Pages 34-39

  Tsujioka, Hiroshi ^a   Suehiro, Akira ^a   Kakishita, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Activated factor VII; Clotting time; Tissue type plasminogen activator

Indexed keywords

BLOOD CLOTTING FACTOR 8; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WESTERN BLOTTING;

BLOOD COAGULATION; BLOTTING, WESTERN; FACTOR VII; FACTOR VIIA; HUMANS; KAOLIN; PLASMIN; PLASMINOGEN; PROTHROMBIN TIME; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032944739     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199905)61:1<34::AID-AJH7>3.0.CO;2-T     Document Type: Article

References (29)

1. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988;319:925-931.
2. Topol EJ, Morris DC, Swalling RW, Schumacher RR, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossberd EB, O'Neill WW. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 1987; 9:1205-1213.
3. Mueller HS, Rao AK, Forman SA, TIMI iInvestigators. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987;10: 479-490.
4. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
5. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the asset study group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1988;2: 525-530.
6. ISIS-2 (second international study of infarct survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
7. Suehiro A, Oura Y, Ueda M, Kakishita E. Inhibitory effect of staphylokinase on platelet aggregation. Thromb Haemost 1993;70:834-837.
8. Suehiro A, Higasa S, Ueda M, Oura Y, Nishida Y, Kakishita E. Effect of plasminogen activator on platelet aggregation. Current aspects of blood coagulation, fibrinolysis and platelets. Shen M-C, Teng C-M, Takada A, editors. Tokyo: Springer; 1993. p 159-164.
9. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616-620.
10. Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988;82:1700-1707.
11. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79:980-989.
12. Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990;335:481-482.
13. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989;55:635-643.
14. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991;83:937-944.
15. Munkvad S, Gram J, Jespersen J. Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study. Scand J Clin Lab Invest 1991; 51:581-590.
16. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992;19:1065-1069.
17. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91:28-36.
18. Laake K, Osterud B. Activation of purified factor VII by human plasmin, plasma kallikrein, and activation components of the human intrinsic blood coagulation system. Thromb Res 1974;5:759-772.
19. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T. Mechanism of activation of coagulation induced by tissue-type plasminogen activator. Studies by using coagulation factor deficient plasma. Jpn J Thromb Haemost 1995;6:453-457.
20. Singer JW, Sibley CA. Sensitivity of commercial thromboplastins to factor VII. Am J Clin Pathol 1973;59:755-759.
21. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961;36:212-219.
22. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of FVIIa in hemophilia A and B patients. Blood 1992;80:25-28.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
24. Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975;388-395.
25. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
26. Lee CD, Mann KG. Activation/Inactivation of human factor V by plasmin. Blood 1989;73:185-190.
27. Bebber KH, Zimmermann RE. Procoagulatory effects of plasmin: factor X and prothrombin activation [abstract]. Ann Hematol 1991;1 (Suppl):A42.
28. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
29. De Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Bescos LL, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.